Please assess the completion status of the following clinical trial:

Trial Title: Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have newly diagnosed, previously untreated Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Grade 3B Follicular lymphoma, Burkitt Lymphoma, Peripheral T cell Lymphoma NOS, NK/T cell Lymphoma, or Transformed lymphoma.~2. Planned to receive chemotherapy for 6 cycles which the treating physician plans to utilize for pegfilgrastim to minimize risk for neutropenic fever, including but not limited to R-CHOP, R-EPOCH, and R-HyperCVAD, CHOP, and SMILE.~3. Age \>= 18 years old.~4. ECOG performance status 0-3.~5. Ability to provide informed consent for participation.~Exclusion Criteria:~1. Existing chronic bone pain prior to pegfilgrastim usage.~2. Creatinine clearance of \<50ml/minute by Cockcroft Gault equation.~3. Allergy to filgrastim, pegfilgrastim, or Loratadine.~4. Chronic daily usage of antihistamine without an acceptable alternative non-antihistamine medication.~5. Inability to swallow medications.~6. Inability to complete the survey instrumentation accurately.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 - Loratadine (Type: EXPERIMENTAL): Pegfilgrastim 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.~Cycle 1 and 3:~Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Cycle 2 and 4:~Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs.
- Group 2 - Placebo (Type: EXPERIMENTAL): Pegfilgrastim 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.~Cycle 1 and 3:~Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Cycle 2 and 4:~Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs.

Based on this trial design, predict the completion outcome and termination type (if applicable).